Eleven Biotherapeutics

Eleven Biotherapeutics

Based: Cambridge, MA
Raised: $25.5 million
Investors: Flagship Ventures, JAFCO, Third Rock Ventures

The scoop: The biotech got started a couple of years ago after the founding venture groups brought some of the top minds in protein engineering to the table. They've been engineering the first protein therapy for ophthalmology--an IL-1 receptor inhibitor--that can be delivered with an eye dropper. And the developer plans to follow up with another ophthalmology candidate that will trail the lead program by about 12 months. Eleven was named a Fierce 15 company in 2010.
 

Eleven Biotherapeutics
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.